Evaluation of the benzothiazole aggregation inhibitors riluzole and PGL-135 as therapeutics for Huntington's disease.

@article{Hockly2006EvaluationOT,
  title={Evaluation of the benzothiazole aggregation inhibitors riluzole and PGL-135 as therapeutics for Huntington's disease.},
  author={Emma Hockly and Jamie Tse and Amy L Barker and Donna L Moolman and Jean-Luc Beunard and Adrian P Revington and Kim Holt and Sunny Sunshine and Hilary Moffitt and Kirupa Sathasivam and Benjamin Woodman and Erich E. Wanker and Philip A. S. Lowden and Gillian P Bates},
  journal={Neurobiology of disease},
  year={2006},
  volume={21 1},
  pages={228-36}
}
Huntington's disease (HD) is an inherited progressive neurological disorder for which there is no effective therapy. It is caused by a CAG/polyglutamine repeat expansion that leads to abnormal protein aggregation and deposition in the brain. Several compounds have been shown to disrupt the aggregation process in vitro, including a number of benzothiazoles… CONTINUE READING